中文名稱:米托蒽醌 | 英文名稱:Mitoxantrone |
CAS:65271-80-9 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: keep away from direct sunlight,store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 98.74% | 產(chǎn)品類別: 抑制劑 |
貨號: T6588 |
名稱 | Mitoxantrone |
描述 | Mitoxantrone (mitozantrone) is an inhibitor of topoisomerase II (Topo II), an inhibitor of protein kinase C (PKC) (IC50=8.5 μM). Mitoxantrone has antitumor activity for the treatment of acute myeloid leukemia, hepatocellular carcinoma, and breast cancer. |
細胞實驗 | The human breast carcinoma cell lines MDA-MB-231 and MCF-7 are seeded in standard 96-well plates. One day after seeding, the culture medium is changed and replaced by medium containing different concentration of Mitoxantrone (10-5 to 5 μM) with or without DHA (30 μM) during 7 days. Viability of cells are measured as a whole by the tetrazolium salt assay[3]. |
激酶實驗 | activity-based protein profiling (ABPP): Mouse brains are Dounce-homogenized in PBS, pH7.5, followed by a low-speed spin (1,400×, 5 min) to remove debris. The supernatant is then subjected to centrifugation (64,000×, 45 min) to provide the cytosolic fraction in the supernatant and the membrane fraction as a pellet. The pellet is washed and resuspended in PBS buffer by sonication. Total protein concentration in each fraction is determined using a protein assay kit. Samples are stored at -80 °C until use. Mouse brain membrane proteomes, are diluted to 1 mg/mL in PBS and pre-incubated with varying concentrations of inhibitors (1 nM to 10 mM) for 30 min at 37 °C before the addition of FP-rhodamine at a final concentration of 2 mM in a 50 mL total reaction volume. After 30 min at 25 °C, the reactions are quenched with 4×SDS-PAGE loading buffer, boiled for 5 min at 90 °C, subjected to SDS-PAGE and visualized in-gel using a flatbed fluorescence s |
體外活性 | 方法:人乳腺癌細胞 MCF7 用 Mitoxantrone (0.07-9.36 μM) 處理 48 h,使用 SRB assay 測定細胞活力。 結果:MCF7 細胞在 Mitoxantrone 1.17 μM 劑量下達到對應于 IC50 的抑制作用。[1] 方法:骨肉瘤細胞 U2OS 用 Mitoxantrone (0.2-1 μM) 處理 48 h,使用 Western Blot 檢測靶點蛋白表達水平。 結果:Mitoxantrone 處理增加了 Caspase-3 和 PARP1 的裂解。Mitoxantrone 處理還增加了骨肉瘤細胞中 Bax 和 Bim EL 的表達。然而,Mitoxantrone 處理降低了 Bcl-2 的表達。[2] |
體內活性 | 方法:為測試對,將 Mitoxantrone (0.4-3.2 mg/kg) 腹腔注射給注射白血病細胞 L1210 的 CDF1 小鼠,每天一次。 結果:以最佳劑量 (1.6 mg/kg/天) 給予 Mitoxantrone 產(chǎn)生了具有統(tǒng)計學意義的 60 天存活率。[3] |
存儲條件 | keep away from direct sunlight,store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 88 mg/mL (197.98 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
關鍵字 | leukaemia | NSC301739 | PKC | MCF-7 | NSC 301739 | lymphocytes | Topoisomerase | HL60 cells | NSC-301739 | B-CLL cells | Protein kinase C | inhibit | Orthopoxvirus | antitumor | Endogenous Metabolite | Mitoxantrone | Apoptosis | breast cancer | Inhibitor |
相關產(chǎn)品 | Prulifloxacin | Norfloxacin | Ciprofloxacin | Berberine chloride | Etoposide | Ciprofloxacin monohydrochloride | EIDD-1931 | α-Vitamin E | Flumequine | Enoxacin |
相關庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | 激酶抑制劑庫 | FDA 上市藥物庫 | TGF-β/Smad靶點化合物庫 | 藥物功能重定位化合物庫 | 疼痛相關化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.2651萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 化學試劑,生物活性小分子 | 經(jīng)營模式 | 貿(mào)易,試劑,定制,服務 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥800 |
VIP10年
|
湖北康恩化學有限公司
|
2024-10-31 | |
詢價 |
VIP5年
|
上海澤葉生物科技有限公司
|
2024-10-31 | |
詢價 |
VIP1年
|
廣州佳途科技股份有限公司
|
2024-10-23 | |
詢價 |
VIP4年
|
山東八方化工科技有限公司
|
2024-10-06 | |
詢價 |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
詢價 |
VIP5年
|
陜西締都醫(yī)藥化工有限公司
|
2024-09-24 | |
¥299.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-08-16 | |
詢價 |
湖北諾迪納生物技術有限公司
|
2024-07-28 |